JP2016515527A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515527A5 JP2016515527A5 JP2016503225A JP2016503225A JP2016515527A5 JP 2016515527 A5 JP2016515527 A5 JP 2016515527A5 JP 2016503225 A JP2016503225 A JP 2016503225A JP 2016503225 A JP2016503225 A JP 2016503225A JP 2016515527 A5 JP2016515527 A5 JP 2016515527A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- deficiency
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 14
- 230000007812 deficiency Effects 0.000 claims description 12
- 239000000090 biomarker Substances 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 230000002438 mitochondrial effect Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000013200 Stress disease Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 208000029560 autism spectrum disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000036542 oxidative stress Effects 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 4
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 4
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 claims description 4
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims description 4
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 4
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 4
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 4
- -1 —O—C 1 -C 4 Chemical group 0.000 claims description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010061323 Optic neuropathy Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000020911 optic nerve disease Diseases 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims description 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 claims description 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims description 2
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims description 2
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 claims description 2
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 208000021075 Creatine deficiency syndrome Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000028782 Hereditary disease Diseases 0.000 claims description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims description 2
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
- 101000603761 Homo sapiens Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 claims description 2
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000025069 Juvenile Huntington disease Diseases 0.000 claims description 2
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims description 2
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims description 2
- 208000035719 Maculopathy Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010059521 Methylmalonic aciduria Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000013234 Pearson syndrome Diseases 0.000 claims description 2
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 claims description 2
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 230000007950 acidosis Effects 0.000 claims description 2
- 208000026545 acidosis disease Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims description 2
- 201000008609 cerebral creatine deficiency syndrome Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000035110 classic form autosomal dominant optic atrophy Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000034737 hemoglobinopathy Diseases 0.000 claims description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 208000038015 macular disease Diseases 0.000 claims description 2
- 201000003694 methylmalonic acidemia Diseases 0.000 claims description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 2
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
- 208000001749 optic atrophy Diseases 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims description 2
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims description 2
- 230000035806 respiratory chain Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 2
- 201000005943 Barth syndrome Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 0 *c(c(*)c1N=C2C(*)=C3*)c(*)c(*)c1OC2=C(*)C3=O Chemical compound *c(c(*)c1N=C2C(*)=C3*)c(*)c(*)c1OC2=C(*)C3=O 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010051403 Mitochondrial DNA deletion Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 201000007998 methylmalonic aciduria and homocystinuria type cblC Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 208000019880 recessive mitochondrial ataxia syndrome Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/837,872 US9296712B2 (en) | 2013-03-15 | 2013-03-15 | Resorufin derivatives for treatment of oxidative stress disorders |
| US13/837,872 | 2013-03-15 | ||
| PCT/US2014/029809 WO2014145118A1 (en) | 2013-03-15 | 2014-03-14 | Resorufin derivatives for treatment of oxidative stress disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016515527A JP2016515527A (ja) | 2016-05-30 |
| JP2016515527A5 true JP2016515527A5 (https=) | 2017-04-27 |
Family
ID=50629004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503225A Pending JP2016515527A (ja) | 2013-03-15 | 2014-03-14 | 酸化ストレス障害の処置のためのレゾルフィン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9296712B2 (https=) |
| EP (1) | EP2970238A1 (https=) |
| JP (1) | JP2016515527A (https=) |
| CA (1) | CA2906150A1 (https=) |
| HK (1) | HK1220449A1 (https=) |
| WO (1) | WO2014145118A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US20170334865A1 (en) * | 2014-10-31 | 2017-11-23 | Washington University | Ddr2 inhibitors and methods of using |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018129411A1 (en) * | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE840115L (en) | 1983-01-21 | 1984-07-21 | Merck Frosst Canada Inc | Phenothiazine derivatives and analogs |
| US4939145A (en) | 1983-01-21 | 1990-07-03 | Merck Frosst Canada, Inc. | Phenothiazone derivatives and analogs |
| US4667032A (en) | 1983-01-21 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazone derivatives and analogs |
| NZ206795A (en) | 1983-01-21 | 1987-08-31 | Merck Frosst Canada Inc | Phenothiazines, analogues and pharmaceutical compositions |
| US4859667A (en) | 1983-01-21 | 1989-08-22 | Merck Frosst Canada, Inc. | Pharmaceutical compositions of phenothiazone derivatives and analogs |
| US4548927A (en) | 1983-05-25 | 1985-10-22 | Eaton John W | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics |
| EP0138481B1 (en) | 1983-10-05 | 1991-06-26 | Merck Frosst Canada Inc. | Leukotriene biosynthesis inhibitors |
| EP0155623A3 (en) | 1984-03-19 | 1985-12-27 | Merck & Co. Inc. | Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition |
| JPS60209520A (ja) * | 1984-03-19 | 1985-10-22 | メルク エンド カムパニー インコーポレーテツド | リポキシゲナーゼ阻害剤の細胞保護的使用 |
| DE3644401A1 (de) | 1986-12-24 | 1988-07-07 | Boehringer Mannheim Gmbh | Neue hydrolase-substrate |
| SK282144B6 (sk) | 1994-12-28 | 2001-11-06 | Janssen Pharmaceutica N. V. | Liečivo na terapeutické a profylaktické ošetrenie degeneratívnych chorôb vaskulárneho systému a nervovej sústavy, ktoré súvisia s oxidačným stresom |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| WO2002047680A2 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| WO2003015494A2 (en) | 2001-08-21 | 2003-02-27 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| AU2003210904A1 (en) | 2002-02-07 | 2003-09-02 | Galileo Lab Inc | Cytoprotective benzofuran derivatives |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ， インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
| WO2004087160A1 (en) | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| US8710088B2 (en) * | 2004-02-11 | 2014-04-29 | Max-Delbruck-Centrum Fur Molekulare Medizin | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| FR2875242B1 (fr) * | 2004-09-10 | 2006-11-17 | Biomerieux Sa | Nouveaux substrats enzymatiques derives de phenoxazinone et leur utilisation comme revelateur dans la detection de microorganismes a activite peptidase |
| DE102004046027A1 (de) * | 2004-09-21 | 2006-03-23 | Henkel Kgaa | Neue direktziehende Farbstoffe |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| CA2622523C (en) | 2005-09-15 | 2014-02-18 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2008086025A2 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| WO2009088572A2 (en) | 2008-01-07 | 2009-07-16 | Centocor, Inc. | Method of treating erythropoietin hyporesponsive anemias |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS |
| CA2723621A1 (en) | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| WO2009143268A2 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| WO2010005989A1 (en) | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EP2424360A4 (en) | 2009-04-28 | 2012-10-03 | Ampere Life Sciences Inc | TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES |
| JP2012525397A (ja) | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| EP2609921A1 (en) | 2009-06-25 | 2013-07-03 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
| DK2470168T3 (en) | 2009-08-26 | 2018-05-07 | Bioelectron Tech Corp | PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM |
| WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
| US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| AU2011238525A1 (en) | 2010-04-06 | 2012-11-08 | Edison Pharmaceuticals, Inc. | Treatment of Ataxia Telangiectasia |
| CA2797581A1 (en) | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
| US20120101169A1 (en) | 2010-07-14 | 2012-04-26 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| EA201300215A1 (ru) | 2010-08-06 | 2013-07-30 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных болезней нафтохинонами |
| EP2601168A4 (en) | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| CA2830581A1 (en) | 2011-04-04 | 2012-10-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Multifunctional radical quenchers for the treatment of mitochondrial dysfunction |
| CA2865316A1 (en) | 2011-04-28 | 2012-11-01 | Gino Cortopassi | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012166862A1 (en) * | 2011-06-01 | 2012-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods for treating alzheimer's disease |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| US20150057363A1 (en) | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
-
2013
- 2013-03-15 US US13/837,872 patent/US9296712B2/en not_active Expired - Fee Related
-
2014
- 2014-03-14 JP JP2016503225A patent/JP2016515527A/ja active Pending
- 2014-03-14 WO PCT/US2014/029809 patent/WO2014145118A1/en not_active Ceased
- 2014-03-14 CA CA2906150A patent/CA2906150A1/en not_active Abandoned
- 2014-03-14 HK HK16108425.0A patent/HK1220449A1/zh unknown
- 2014-03-14 EP EP14720843.3A patent/EP2970238A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515527A5 (https=) | ||
| JP2016514697A5 (https=) | ||
| JP2016515526A5 (https=) | ||
| JP2016520621A5 (https=) | ||
| JP2015533794A5 (https=) | ||
| JP2019504018A5 (https=) | ||
| JP2018500326A5 (https=) | ||
| DE69522972T2 (de) | Fettamin Derivate von Sorbinsäure für den Schutz von Oberflächen gegen physische und chemikalische Degradierung | |
| JP2016525093A5 (https=) | ||
| JP2013091672A5 (https=) | ||
| MX353957B (es) | Carboxamidas heterociclicas fungicidas. | |
| US20220386724A1 (en) | Antimicrobial dyes for healthcare apparel | |
| JP2010526831A5 (https=) | ||
| JPH0764786B2 (ja) | フェノール系化合物およびこれを有効成分とするブタジエン系ポリマー用安定剤 | |
| JP2021524440A5 (https=) | ||
| NZ601967A (en) | Pde10 inhibitors and related compositions and methods | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| JP2017534665A5 (https=) | ||
| AR106589A1 (es) | Derivados de indolin-2-ona | |
| JP2008536844A5 (https=) | ||
| CN114269838B (zh) | 抗微生物医用手套 | |
| IE67814B1 (en) | Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases | |
| JP2010529167A5 (https=) | ||
| JPH0725947B2 (ja) | ブタジエン系ポリマー組成物 | |
| JP2010509341A5 (https=) |